{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:49:55Z","timestamp":1790070595988,"version":"4.0.1"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T00:00:00Z","timestamp":1499990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Demonstration of clinical effectiveness of a non\u2010Hodgkin's lymphoma (NHL) treatment generally involves determination of progression\u2010free survival (PFS). However, the long evaluation time of PFS limits its utility to make timely decisions in drug development. Therefore, the objective of this analysis was to determine the relationship between response rates and median PFS in NHL. A database was systematically developed from 513 identified NHL trials reported from 1996 to 2015. Potential predictors of the relationship between response rates and PFS were evaluated, including age, sex, treatment, percentage of treatment\u2010na\u00efve patients, and subtype of NHL. Seventy\u2010three trials involving 86 cohorts were included in the meta\u2010analysis. Linear regression analysis using logit of response rates and logarithm of median PFS indicated that the correlation between overall response rate (ORR) and median PFS was higher (<jats:italic>R<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u00a0=\u00a00.70) when compared to that of complete response (CR) rate and median PFS (<jats:italic>R<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u00a0=\u00a00.57). Furthermore, the correlation was improved with the addition of percentage of treatment\u2010na\u00efve patients and percentage of patients with follicular lymphoma (FL) (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.005) between ORR and median PFS (<jats:italic>R<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u00a0=\u00a00.78), and between CR rate and median PFS relationship (<jats:italic>R<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u00a0=\u00a00.74). Treatment was not found to alter this relationship. In summary, ORR is as good as CR rate in predicting median PFS. Moreover, longer median PFS is expected in the trials including treatment\u2010na\u00efve and\/or FL patients at a given ORR\/CR rate. The determined relationship can be used to project the median PFS based on ORR or CR rate.<\/jats:p>","DOI":"10.1002\/hon.2463","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T08:12:42Z","timestamp":1500019962000},"page":"37-43","source":"Crossref","is-referenced-by-count":20,"title":["Relationship between response rates and median progression\u2010free survival in non\u2010Hodgkin's lymphoma: A meta\u2010analysis of published clinical trials"],"prefix":"10.1002","volume":"36","author":[{"given":"Naveen","family":"Mangal","sequence":"first","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology University of Florida  Orlando FL USA"},{"name":"Abbvie, Inc.  North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[{"name":"Abbvie, Inc.  North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Li","sequence":"additional","affiliation":[{"name":"Abbvie, Inc.  North Chicago IL USA"},{"name":"Merck and Co.  Rahway NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Menon","sequence":"additional","affiliation":[{"name":"Abbvie, Inc.  North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Freise","sequence":"additional","affiliation":[{"name":"Abbvie, Inc.  North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,14]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Guidance for Industry. Clinical Trail Endpoints for the Approval of Cancer Drugs and Biologics","author":"Food and Drug Administration (FDA)","year":"2007"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviscsurg.2013.10.001"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S36683"},{"issue":"15","key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/jco.2015.33.15_suppl.8504","article-title":"Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression\u2010free survival (PFS) in first\u2010line follicular lymphoma (FL) studies: results from the prospectively specified follicular lymphoma analysis of surrogacy hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts)","volume":"33","author":"Sargent DJ","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70375-4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0297"},{"key":"e_1_2_7_8_1","unstructured":"ZupnikA.Overcoming hematological oncology clinical trial challenges.http:\/\/wwwappliedclinicaltrialsonlinecom\/overcoming\u2010hematological\u2010oncology\u2010clinical\u2010trial\u2010challenges?pageID=2;2014."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-S1-13"},{"key":"e_1_2_7_10_1","volume-title":"Guideline on Evaluation of Anticancer Medicinal Products in Man","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2016"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp515"},{"key":"e_1_2_7_12_1","first-page":"1","article-title":"Oncology endpoints in a changing landscape","volume":"1","author":"Editorial","year":"2016","journal-title":"Manag Care"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282034"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0235"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.012161"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0489"},{"key":"e_1_2_7_17_1","unstructured":"HigginsJPT GreenS (eds.)Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration;2011. Available from www.cochrane\u2010handbook.org.;s"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5913"},{"issue":"21","key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood.V120.21.2724.2724","article-title":"Subanalysis of the StiL NHL 1\u20132003 study: achievement of complete response with bendamustine\u2010rituximab (B\u2010R) and CHOP\u2010R in the first\u2010line treatment of indolent and mantle cell lymphomas results in superior survival compared to partial response","volume":"120","author":"Rummel MJ","year":"2012","journal-title":"Blood"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.2829"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq615"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds289"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2502"},{"issue":"2","key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/1078-0432.CCR-14-1779","article-title":"Meta\u2010analysis for the association between overall survival and progression\u2010free survival in gastrointestinal stromal tumor","volume":"21","author":"Ozer\u2010Stillman I","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3747\/co.22.2119","article-title":"Relationship between progression\u2010free survival and overall survival in chronic lymphocytic leukemia: a literature\u2010based analysis","volume":"22","author":"Beauchemin C","year":"2015","journal-title":"Curr Oncol"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11534"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000375392"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0276"},{"key":"e_1_2_7_31_1","unstructured":"ZhuR LuD ChuW et al.Potential surrogate endpoints for progression\u2010free survival (PFS) and overall survival (OS) in non\u2010Hodgkin lymphoma: a literature\u2010based meta\u2010analysis of phase II and phase III studies. Poster presented at the 5th American conference on pharmacometrics meeting Las Vegas NV;2014. Available at:http:\/\/www.acop7.org\/assets\/Legacy_ACOPs\/ACOP5\/Poster_Abstracts\/w\u2010017.pdf"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70380-8"},{"issue":"22","key":"e_1_2_7_35_1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.V128.22.471.471","article-title":"First analysis of an international double\u2010blind randomized phase III study of lenalidomide maintenance in elderly patients with DLBCL treated with R\u2010CHOP in first line, the Remarc study from Lysa","volume":"128","author":"Thieblemont C","year":"2016","journal-title":"Blood"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1002%2Fhon.2463","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:56:01Z","timestamp":1695552961000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,14]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/hon.2463"],"URL":"https:\/\/doi.org\/10.1002\/hon.2463","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,14]]}}}